Loading...

Biotage

DB:PQX1
Snowflake Description

Excellent balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PQX1
DB
SEK7B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Biotage AB (publ), a life science company, provides solutions, knowledge, and experience in the areas of organic and analytical chemistry, as well as for industrial applications in the United States, Europe, Japan, China, and internationally. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
  • Biotage has significant price volatility in the past 3 months.
PQX1 Share Price and Events
7 Day Returns
-5.2%
DB:PQX1
2.7%
Europe Life Sciences
0.7%
DE Market
1 Year Returns
-5.4%
DB:PQX1
21.3%
Europe Life Sciences
-8.7%
DE Market
PQX1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biotage (PQX1) -5.2% -8.5% -17.7% -5.4% 218.9% 736.9%
Europe Life Sciences 2.7% 2.5% 10.4% 21.3% 84.6% 204.2%
DE Market 0.7% -1.2% 0.2% -8.7% 10% 8.1%
1 Year Return vs Industry and Market
  • PQX1 underperformed the Life Sciences industry which returned 21.3% over the past year.
  • PQX1 outperformed the Market in Germany which returned -8.7% over the past year.
Price Volatility
PQX1
Industry
5yr Volatility vs Market

Value

 Is Biotage undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Biotage to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Biotage.

DB:PQX1 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:PQX1
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 0.99
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.989 (1 + (1- 22%) (2.4%))
1.005
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.01
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.005 * 5.96%)
6.22%

Discounted Cash Flow Calculation for DB:PQX1 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Biotage is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:PQX1 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 6.22%)
2019 201.00 Analyst x1 189.23
2020 215.00 Analyst x1 190.56
2021 217.00 Analyst x1 181.07
2022 218.56 Est @ 0.72% 171.69
2023 219.80 Est @ 0.57% 162.56
2024 220.83 Est @ 0.47% 153.76
2025 221.70 Est @ 0.4% 145.33
2026 222.47 Est @ 0.35% 137.29
2027 223.16 Est @ 0.31% 129.65
2028 223.80 Est @ 0.29% 122.41
Present value of next 10 years cash flows SEK1,583.55
DB:PQX1 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= SEK223.80 × (1 + 0.23%) ÷ (6.22% – 0.23%)
SEK3,743.80
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK3,743.80 ÷ (1 + 6.22%)10
SEK2,047.73
DB:PQX1 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK1,583.55 + SEK2,047.73
SEK3,631.28
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK3,631.28 / 65.20
SEK55.69
DB:PQX1 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:PQX1 represents 0.09279x of OM:BIOT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.09279x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 55.69 x 0.09279
€5.17
Value per share (EUR) From above. €5.17
Current discount Discount to share price of €10.16
= -1 x (€10.16 - €5.17) / €5.17
-96.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Biotage is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biotage's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biotage's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PQX1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in SEK SEK2.63
OM:BIOT Share Price ** OM (2019-06-19) in SEK SEK109.5
Europe Life Sciences Industry PE Ratio Median Figure of 16 Publicly-Listed Life Sciences Companies 37.98x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.53x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biotage.

DB:PQX1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:BIOT Share Price ÷ EPS (both in SEK)

= 109.5 ÷ 2.63

41.68x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotage is overvalued based on earnings compared to the Europe Life Sciences industry average.
  • Biotage is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Biotage's expected growth come at a high price?
Raw Data
DB:PQX1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 41.68x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
8%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 12 Publicly-Listed Life Sciences Companies 2.7x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.49x

*Line of best fit is calculated by linear regression .

DB:PQX1 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 41.68x ÷ 8%

5.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotage is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Biotage's assets?
Raw Data
DB:PQX1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in SEK SEK12.69
OM:BIOT Share Price * OM (2019-06-19) in SEK SEK109.5
Europe Life Sciences Industry PB Ratio Median Figure of 35 Publicly-Listed Life Sciences Companies 2.5x
Germany Market PB Ratio Median Figure of 575 Publicly-Listed Companies 1.78x
DB:PQX1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:BIOT Share Price ÷ Book Value per Share (both in SEK)

= 109.5 ÷ 12.69

8.63x

* Primary Listing of Biotage.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotage is overvalued based on assets compared to the Europe Life Sciences industry average.
X
Value checks
We assess Biotage's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Biotage has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Biotage expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biotage expected to grow at an attractive rate?
  • Biotage's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Biotage's earnings growth is positive but not above the Germany market average.
  • Biotage's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:PQX1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PQX1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 8%
DB:PQX1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 10.4%
Europe Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 14.8%
Europe Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PQX1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PQX1 Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 1,274 278 217 1
2020-12-31 1,154 271 212 1
2019-12-31 1,052 252 200 1
DB:PQX1 Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-03-31 951 139 170
2018-12-31 911 155 168
2018-09-30 865 170 175
2018-06-30 811 149 162
2018-03-31 771 168 148
2017-12-31 748 169 139
2017-09-30 738 145 122
2017-06-30 728 145 118
2017-03-31 694 131 105
2016-12-31 668 139 93
2016-09-30 657 130 96
2016-06-30 640 133 87

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Biotage's earnings are expected to grow by 8% yearly, however this is not considered high growth (20% yearly).
  • Biotage's revenue is expected to grow by 10.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PQX1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Biotage Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PQX1 Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 3.32 3.32 3.32 1.00
2020-12-31 3.24 3.24 3.24 1.00
2019-12-31 3.06 3.06 3.06 1.00
DB:PQX1 Past Financials Data
Date (Data in SEK Millions) EPS *
2019-03-31 2.63
2018-12-31 2.59
2018-09-30 2.70
2018-06-30 2.50
2018-03-31 2.29
2017-12-31 2.14
2017-09-30 1.88
2017-06-30 1.83
2017-03-31 1.63
2016-12-31 1.43
2016-09-30 1.48
2016-06-30 1.34

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Biotage is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Biotage's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biotage has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Biotage performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biotage's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biotage has delivered over 20% year on year earnings growth in the past 5 years.
  • Biotage's 1-year earnings growth is less than its 5-year average (14.8% vs 25.4%)
  • Biotage's earnings growth has not exceeded the Europe Life Sciences industry average in the past year (14.8% vs 14.8%).
Earnings and Revenue History
Biotage's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biotage Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PQX1 Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 950.87 170.29 337.06 69.54
2018-12-31 910.90 167.63 323.64 65.93
2018-09-30 865.21 174.95 306.92 59.47
2018-06-30 810.72 162.05 289.25 59.55
2018-03-31 770.97 148.31 272.14 56.29
2017-12-31 748.15 138.75 259.83 55.99
2017-09-30 738.41 121.59 261.54 52.91
2017-06-30 727.72 118.16 258.86 52.37
2017-03-31 694.27 105.22 252.66 51.87
2016-12-31 667.91 92.80 245.27 49.19
2016-09-30 657.31 96.02 233.75 51.87
2016-06-30 639.98 86.60 229.55 51.19
2016-03-31 625.23 77.52 223.94 48.60
2015-12-31 610.53 73.26 221.61 49.53
2015-09-30 579.74 82.69 213.87 47.12
2015-06-30 548.57 75.41 203.93 44.36
2015-03-31 520.84 75.15 195.71 42.83
2014-12-31 490.38 64.61 186.85 38.45
2014-09-30 474.27 52.94 181.57 34.60
2014-06-30 459.17 48.86 178.12 33.55
2014-03-31 455.13 46.38 178.27 33.86
2013-12-31 444.64 41.39 177.40 33.48
2013-09-30 436.94 36.52 178.22 33.39
2013-06-30 440.65 33.27 180.93 34.78
2013-03-31 446.60 33.55 184.51 36.60
2012-12-31 462.94 38.62 189.28 36.85
2012-09-30 465.03 34.87 188.67 37.18
2012-06-30 464.45 42.64 190.82 35.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Biotage has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Biotage used its assets more efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • Biotage has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Biotage's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biotage has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Biotage's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biotage's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biotage is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biotage's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Biotage's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biotage Company Filings, last reported 2 months ago.

DB:PQX1 Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 827.63 171.23 142.60
2018-12-31 702.18 109.40 177.02
2018-09-30 673.58 109.36 134.06
2018-06-30 632.40 109.33 95.84
2018-03-31 659.55 109.29 168.89
2017-12-31 608.61 0.00 174.26
2017-09-30 569.64 0.00 119.55
2017-06-30 545.68 0.00 101.64
2017-03-31 595.94 0.00 152.10
2016-12-31 563.24 0.00 128.62
2016-09-30 539.51 0.00 101.33
2016-06-30 510.27 0.00 99.57
2016-03-31 564.19 0.00 163.48
2015-12-31 546.66 0.00 134.89
2015-09-30 514.09 5.14 115.72
2015-06-30 496.10 5.00 90.31
2015-03-31 530.64 5.11 120.81
2014-12-31 516.15 5.04 100.05
2014-09-30 480.76 5.06 77.99
2014-06-30 464.73 5.09 66.91
2014-03-31 484.63 4.96 92.35
2013-12-31 476.77 5.74 90.77
2013-09-30 463.04 5.68 86.23
2013-06-30 468.93 5.90 88.63
2013-03-31 518.15 5.09 159.09
2012-12-31 530.83 5.56 170.92
2012-09-30 528.71 5.78 162.82
2012-06-30 536.50 6.10 164.36
  • Biotage's level of debt (13.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (1% vs 13.2% today).
  • Debt is well covered by operating cash flow (127.3%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 59.9x coverage).
X
Financial health checks
We assess Biotage's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biotage has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Biotage's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.37%
Current annual income from Biotage dividends. Estimated to be 1.64% next year.
If you bought €2,000 of Biotage shares you are expected to receive €27 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Biotage's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.45%).
  • Biotage's dividend is below the markets top 25% of dividend payers in Germany (3.91%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PQX1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PQX1 Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 2.00 1.00
2020-12-31 1.80 1.00
2019-12-31 1.60 1.00
DB:PQX1 Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2019-03-25 1.500 1.245
2018-04-27 1.400 1.215
2017-04-28 1.250 1.810
2016-03-22 1.000 2.681
2016-02-11 1.000 3.906
2015-03-26 0.750 3.963
2014-03-26 0.600 4.986
2013-04-26 0.500 5.124
2012-04-27 0.400 4.944
2011-03-25 0.250 4.174
2010-04-30 0.200 2.833

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Biotage has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Biotage only paid a dividend in the past 9 years.
Current Payout to shareholders
What portion of Biotage's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.8x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.8x coverage).
X
Income/ dividend checks
We assess Biotage's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biotage afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biotage has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Biotage's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Torben Jörgensen
COMPENSATION SEK6,417,791
AGE 66
TENURE AS CEO 13.2 years
CEO Bio

Mr. Torben Jörgensen, B.Sc., has been the Chief Executive Officer and President of Biotage AB since April 27, 2006 and serves as its Group Director.He served as the Managing Director and President of The Business Area Discovery Chemistry at Karo Bio USA, Inc. since April 1, 2006. He served as the Chief Executive Officer of Affibody Technology Ab. Mr. Jörgensen served as Co-President of Business Area Discovery Chemistry of Biotage AB since February 28, 2006. He has 17 years executive management experience as Chief Executive Officer, Chief Financial Officer and Board member at several Life Science companies. He served as Chief Executive Officer and President of the Swedish publicly listed biotechnology company Karo Bio AB. He served as first Chief Financial Officer and then, for 9 years, Chief Executive Officer of Dako AS, a Danish Antibody and Diagnostics Company. He served as the Chief Executive Officer of Affibody AB from 2001 to 2005. Mr. Jorgensen has more than 10 years of experience from sales and marketing of antibody research reagents and diagnostic products as Chief Executive Officer of the Danish company Dako from 1989 to 1999. He serves as Chairman of the Board and Director of MIP Technologies Ab. He serves as a Director of Atlas Antibodies AB. He holds business degree from the Business School of Copenhagen.

CEO Compensation
  • Torben's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Torben's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Biotage management team in years:

10.8
Average Tenure
54
Average Age
  • The average tenure for the Biotage management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Torben Jörgensen

TITLE
CEO, President & Group Director
COMPENSATION
SEK6M
AGE
66
TENURE
13.2 yrs

Erika Johnson

TITLE
Chief Financial Officer
AGE
48
TENURE
7.4 yrs

Anders Wikström

TITLE
Vice President of Operations
AGE
45
TENURE
9.1 yrs

Steve Jordan

TITLE
Chief Scientific Officer
AGE
65

Lars Bäckman

TITLE
Vice President of Corporate Development
AGE
57
TENURE
12.4 yrs

Rikke Rytter

TITLE
Vice President Global Marketing
AGE
51

Cecilia Hållner

TITLE
Global Human Resources Director
AGE
46

Hans Johansson

TITLE
President of Biosystems
AGE
64

Scott Carr

TITLE
Vice President and Chief Executive Officer of North America

Lei Shi

TITLE
Chief Executive Officer of China
Board of Directors Tenure

Average tenure and age of the Biotage board of directors in years:

1
Average Tenure
57
Average Age
  • The average tenure for the Biotage board of directors is less than 3 years, this suggests a new board.
Board of Directors

Thomas Eklund

TITLE
Chairman
COMPENSATION
SEK250K
AGE
51
TENURE
1.2 yrs

Torben Jörgensen

TITLE
CEO, President & Group Director
COMPENSATION
SEK6M
AGE
66
TENURE
0.2 yrs

Karolina Lawitz

TITLE
Director
COMPENSATION
SEK200K
AGE
62
TENURE
7.2 yrs

Peter von Ehrenheim

TITLE
Director
COMPENSATION
SEK225K
AGE
63
TENURE
6.2 yrs

Love Amcoff

TITLE
Employee Representative Director
AGE
44

Annika Gärdlund

TITLE
Employee Representative Director
AGE
52
TENURE
0.8 yrs

Mark Bradley

TITLE
Director
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Feb 19 Buy Torben Jörgensen Individual 11. Feb 19 11. Feb 19 1,500 €10.29 €15,431
04. Jan 19 Sell Nils-Olof Björk Individual 04. Jan 19 04. Jan 19 -6,000 €10.72 €-64,294
02. Jan 19 Sell Peter von Ehrenheim Individual 02. Jan 19 02. Jan 19 -6,000 €10.87 €-65,213
04. Dec 18 Sell Yvonne Mårtensson Individual 04. Dec 18 04. Dec 18 -10,000 €11.87 €-118,251
04. Dec 18 Buy Yvonne Mårtensson Individual 04. Dec 18 04. Dec 18 2,000 €11.86 €23,722
19. Jul 18 Buy Karolina Lawitz Individual 18. Jul 18 18. Jul 18 2,500 €10.85 €27,128
X
Management checks
We assess Biotage's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biotage has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Biotage AB (publ), a life science company, provides solutions, knowledge, and experience in the areas of organic and analytical chemistry, as well as for industrial applications in the United States, Europe, Japan, China, and internationally. It offers sample preparation solutions; horizon food and environmental products; microwave synthesis solutions; peptide synthesis and purification solutions; flash purification products; work-up products; evaporation and concentration solutions; and metal scavengers, reagents, scavengers, and custom resins. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and academic institutions; and commercial, hospital/bio-analytical, and forensic laboratories, as well as laboratories within food and environmental analysis. The company is headquartered in Uppsala, Sweden.

Details
Name: Biotage AB
PQX1
Exchange: DB
Founded:
SEK670,067,029
65,201,784
Website: http://www.biotage.com
Address: Biotage AB
Box 8,
Uppsala,
Uppsala County, 751 03,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM BIOT Series A Common Stock OMX Nordic Exchange Stockholm SE SEK 30. Jun 2000
OTCPK BITG.F Series A Common Stock Pink Sheets LLC US USD 30. Jun 2000
DB PQX1 Series A Common Stock Deutsche Boerse AG DE EUR 30. Jun 2000
LSE 0GRP Series A Common Stock London Stock Exchange GB SEK 30. Jun 2000
BATS-CHIXE BIOTS Series A Common Stock BATS 'Chi-X Europe' GB SEK 30. Jun 2000
XTRA PQX SEK1 SER'A' XETRA Trading Platform DE EUR 08. Feb 2007
Number of employees
Current staff
Staff numbers
413
Biotage employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/19 21:59
End of day share price update: 2019/06/19 00:00
Last estimates confirmation: 2019/04/24
Last earnings filing: 2019/04/24
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.